Article Text

PDF

PWE-028 Significantly Improved Abdominal Pain (AP) with Linaclotide (LIN) vs Placebo (PBO) in Patients (PTS) with Irritable Bowel Syndrome (IBS) Regardless of Baseline Pain Severity in 2 Phase 3 Trials
  1. J Johnston1,
  2. W D Chey2,
  3. B Lavins1,
  4. S J Shiff3,
  5. C Kurtz1,
  6. J MacDougall1,
  7. X Jia3,
  8. H Schneier3,
  9. M Currie1
  1. 1Ironwood Pharmaceuticals, Cambridge
  2. 2University of Michigan Heath System, Ann Arbor
  3. 3Forest Research Institute, Jersey City, United States

Abstract

Introduction LIN, a 14-amino-acid, minimally absorbed, guanylate cyclase C agonist (GCCA), significantly improved abdominal and bowel symptoms in 2 Phase 3 IBS with constipation (IBS-C) trials. Previous IBS trials of other therapies showed inconsistent effects of baseline AP severity on efficacy. This post-hoc analysis determined the LIN effect on AP stratified by pt-reported baseline AP severity.

Methods Pts with IBS-C (Rome II criteria) were randomised to LIN 290 μg od po or PBO. Pts rated daily AP at its worst during the previous 24h (11-point scale; 0 = none, 10 = very severe) during Baseline and Treatment Periods. Using pooled 12-wk ITT data from 2 Phase 3 trials, pts were stratified by mean baseline AP score (< 5, ≥5- < 7, ≥7). At each post-randomisation visit pts rated their relief of AP over the past wk vs baseline (7-point balanced scale; 1 = completely relieved, 7 = as bad as I can imagine). The Least Squares (LS) mean change from 2-wk Baseline to 12-wk Treatment Period, % improvement, difference estimates and p-values were calculated (ANCOVA; factors = treatment group, geographic region and study. Covariate = baseline AP).

Results Overall, LIN significantly improved 12-wk AP vs PBO. LIN also led to significant benefit in all 3 baseline stratified AP subgroups, with pain score decreases of 29–36% vs 18–20% for PBO (p < 0.0001; Table); improvement was numerically less in pts with milder (< 5) baseline severity. Baseline AP scores significantly correlated with absolute magnitude of change from baseline improvement in AP (r = 0.26; p < 0.0001) but not with % improvement (r = 0.00; p = 0.9184). Pt-rated relief of AP was significantly improved with LIN vs PBO overall (LS mean 2.9 vs 3.5; p < 0.0001); relief of AP was also seen for all 3 baseline AP subgroups (baseline AP < 5: 2.8 vs 3.4; ≥5- < 7: 2.9 vs 3.5; ≥7: 3.0 vs 3.6; p < 0.0001 for all).

Abstract PWE-028 Table 1

Conclusion LIN led to significant absolute and % improvement in AP vs PBO overall and stratified by baseline AP severity. Absolute magnitude of improvement in AP significantly correlated with baseline AP severity; however, all groups had similar % improvement in AP. Pt-rated relief of AP was consistent across baseline AP severity groups. Support: Ironwood Pharmaceuticals Inc & Forest Laboratories Inc. Editing: CMC funded by Almirall

Disclosure of Interest J. Johnston Shareholder of: Ironwood Pharmaceuticals, Employee of: Ironwood Pharmaceuticals, W. Chey Consultant for: Ironwood Pharmaceuticals and Forest Laboratories, B. Lavins Shareholder of: Ironwood Pharmaceuticals, Employee of: Ironwood Pharmaceuticals, S. Shiff Shareholder of: Forest Laboratories, Employee of: Forest Laboratories, C. Kurtz Shareholder of: Ironwood Pharmaceuticals, Employee of: Ironwood Pharmaceuticals, J. MacDougall Shareholder of: Ironwood Pharmaceuticals, Employee of: Ironwood Pharmaceuticals, X. Jia Shareholder of: Forest Laboratories, Employee of: Forest Laboratories, H. Schneier Shareholder of: Forest Laboratories, Employee of: Forest Laboratories, M. Currie Shareholder of: Ironwood Pharmaceuticals, Employee of: Ironwood Pharmaceuticals

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.